{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-084969","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.430416+00:00","generated_at":"2026-06-08T07:53:33.901981+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cadrenal Therapeutics Q3 update: expands tecarfarin to LVAD/APS, cash $9.1M","bullets":["Expanded tecarfarin development beyond ESKD with AFib to include LVAD and APS, adding $1.5B annual U.S. market opportunity.","Total addressable market for tecarfarin now over $2 billion annually in the U.S.","Q3 2023 operating expenses (non-cash) totaled $989,000; cash used in operations $628,000.","Cash balance as of Sept 30, 2023 was $9.1 million, providing flexibility to initiate pivotal trial in 2024.","Completed $7.5 million private placement at $1.75/share in July 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-084969","json":"https://secwatch.observer/filing/0001213900-23-084969.json","markdown":"https://secwatch.observer/filing/0001213900-23-084969.md","text":"https://secwatch.observer/filing/0001213900-23-084969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023084969/0001213900-23-084969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023084969/ea187953-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:53:33.901981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}